Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
24 janv. 2022 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for...
Soleno Therapeutics to Participate in the LifeSci Partners 11th Annual Corporate Access Event
05 janv. 2022 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 nov. 2021 16h05 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results
10 nov. 2021 16h05 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
23 sept. 2021 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics to Participate in the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
16 sept. 2021 16h05 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR
08 sept. 2021 08h00 HE
|
Soleno Therapeutics
Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Study C602 Statistically significant improvements compared to natural history of PWS from the PATH...
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results
28 juil. 2021 16h05 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome
06 juil. 2021 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a
02 juin 2021 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...